Haemonetics (HAE) Tops Q2 EPS by 5c ; Offers Guidance

Haemonetics (NYSE: HAE) reported Q2 EPS of $1.12, $0.05 better than the analyst estimate of $1.07. Revenue for the quarter came in at $346 million versus the consensus estimate of $342.58 million.

GUIDANCE:

Haemonetics sees FY2025 EPS of $4.45-$4.75, versus the consensus of $4.59.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• BofA Securities Upgrades Moderna (MRNA) to Neutral
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• Target raises full-year sales forecast amid ongoing turnaround drive